Recurrent Malignant Solid Neoplasm (DBCOND0082715)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04693468	Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	Axitinib Crizotinib Palbociclib Talazoparib Tyrosine	treatment	1	recruiting
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Alpelisib Binimetinib Fluorouracil Fulvestrant Hydrogen Ipatasertib Leucovorin Neratinib Nilotinib Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Selumetinib Sotorasib Sulfate ion	screening	2	recruiting
NCT06620302	Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma	DT2216 Irinotecan	treatment	1 / 2	not_yet_recruiting
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	ABSK-091 Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib GSK-2636771 Ipatasertib Larotrectinib Methane Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Sulfate ion Sunitinib Taselisib Trametinib Trastuzumab Trastuzumab emtansine Tyrosine Ulixertinib Vismodegib	screening	2	active_not_recruiting
NCT03210714	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Erdafitinib	treatment	2	active_not_recruiting
NCT03213678	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	LY-3023414	treatment	2	active_not_recruiting
NCT03213704	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	Larotrectinib Sulfate ion	treatment	2	active_not_recruiting
NCT04320888	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Selpercatinib	treatment	2	active_not_recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT05286801	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Atezolizumab Tiragolumab	treatment	1 / 2	recruiting
NCT06126276	Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	Neratinib Palbociclib	treatment	2	recruiting
NCT02867592	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Cabozantinib	treatment	2	active_not_recruiting
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Ensartinib Erdafitinib Hydrogen LY-3023414 Larotrectinib Menthol Olaparib Palbociclib Selpercatinib Selumetinib Sulfate ion Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-396	screening	2	recruiting
NCT03213652	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Ensartinib X-396	treatment	2	recruiting
NCT03698994	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Ulixertinib	treatment	2	active_not_recruiting
NCT04195555	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	Ivosidenib	treatment	2	active_not_recruiting
NCT04851119	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Tegavivint	treatment	1 / 2	recruiting
NCT04870944	CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	No drug interventions	treatment	1 / 2	recruiting
NCT05058339	Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer	No drug interventions	Not Available	Not Available	completed
NCT06223542	Studying TAK-243 in Patients With Advanced Cancer	TAK-243	treatment	1	recruiting
NCT03366103	Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	Navitoclax Vistusertib	treatment	1 / 2	terminated
NCT04901702	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma	Irinotecan Talazoparib Temozolomide	treatment	1 / 2	active_not_recruiting
NCT03428802	Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	Pembrolizumab	treatment	2	recruiting
NCT04530487	Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults	Antithymocyte immunoglobulin (rabbit) Beta-D-Glucose Cyclosporine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	terminated
NCT01638533	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction	Romidepsin	treatment	1	active_not_recruiting
NCT03502733	Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma	Copanlisib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT02116777	Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies	Talazoparib Temozolomide	treatment	1 / 2	completed
NCT03927885	Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer	No drug interventions	supportive_care	2 / 3	active_not_recruiting
NCT02095132	Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	Adavosertib Camptothecin Irinotecan	treatment	1 / 2	completed
NCT04267575	Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites	No drug interventions	treatment	Not Available	unknown_status
NCT00939770	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Crizotinib Tyrosine	treatment	1 / 2	completed
NCT04119024	Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT05010096	BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	Copanlisib Elimusertib	treatment	1	withdrawn
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT01709435	Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	Cabozantinib	treatment	1	completed
NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	Allogeneic natural killer cells Beta-D-Glucose Cyclophosphamide Etoposide Natural Killer Cell	treatment	1	recruiting
NCT01822522	Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	Cabozantinib	treatment	1	completed
NCT04500548	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	Ipilimumab Nivolumab	treatment	1	withdrawn
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Tazemetostat	treatment	2	active_not_recruiting
NCT02975882	Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	Albumin human Camptothecin Irinotecan Sirolimus Temozolomide	treatment	1	active_not_recruiting
NCT02474160	Collection and Storage of Tissue and Blood Samples From Patients With Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT04840589	Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	Ipilimumab Nivolumab	treatment	1	recruiting
NCT02143401	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Navitoclax Sorafenib	treatment	1	active_not_recruiting
NCT02780804	Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	Entinostat	treatment	1	completed
NCT03583255	Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer	Dexamethasone	supportive_care	2 / 3	active_not_recruiting
NCT02808650	Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	Prexasertib	treatment	1	completed
NCT04960787	Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses	No drug interventions	health_services_research	Not Available	recruiting
NCT03017833	Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers	Metformin Sapanisertib	treatment	1	completed
NCT02451553	Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer	Afatinib Capecitabine	treatment	1	completed
NCT04871477	Adoption of Audio Recording in the Outpatient Supportive Care Center	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT06320405	Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	Axatilimab Paclitaxel Retifanlimab	treatment	1 / 2	recruiting
NCT05059678	Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis	No drug interventions	supportive_care	Not Available	recruiting
NCT03229278	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Nivolumab Pembrolizumab	treatment	1	completed
NCT03035409	Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors	Anamorelin	supportive_care	2	active_not_recruiting
NCT02389309	Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors	Cyclophosphamide Dasatinib Menthol Sirolimus Temsirolimus	treatment	1	active_not_recruiting
NCT05071209	Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	Elimusertib	treatment	1 / 2	active_not_recruiting
NCT05101356	A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma	Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05091632	Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit	No drug interventions	Not Available	Not Available	suspended
NCT05455606	Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	No drug interventions	health_services_research	Not Available	recruiting
NCT04090619	Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT04171219	Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers	Boron Pembrolizumab Talabostat	treatment	2	active_not_recruiting
NCT03323034	Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Irinotecan Pevonedistat Temozolomide	treatment	1	active_not_recruiting
NCT03220035	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Vemurafenib	treatment	2	active_not_recruiting
NCT03320330	Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	Pepinemab	treatment	1 / 2	completed
NCT06295965	Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers, CHANCES Study	No drug interventions	Not Available	Not Available	recruiting
NCT03212274	Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	Olaparib	treatment	2	active_not_recruiting
NCT03430882	Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors	Carboplatin Paclitaxel Sapanisertib	treatment	1	completed
NCT03213691	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Hydrogen Selumetinib Sulfate ion	treatment	2	active_not_recruiting
NCT02323880	Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	Escitalopram Selinexor	treatment	1	active_not_recruiting
NCT02159989	Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Aflibercept Sapanisertib	treatment	1	completed
NCT03233204	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Olaparib	treatment	2	completed
NCT03205644	VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	Pepinemab	treatment	1 / 2	not_yet_recruiting